| CTMX Stock | | | USD 0.85 0.03 3.41% |
President
Ms. Leslie Robbins, J.D. is Senior Vice President Intellectual Property of the company. Ms. Robbins has over 25 years of legal and intellectual property strategic experience within the biotechnology and pharmaceutical industries. Ms. Robbins joins CytomX from Coherus BioSciences where she held the role of vice president, intellectual property and was responsible for, among other things, the execution of legal strategies in support of the biosimilar platform. Prior to this, she held senior intellectual property counsel roles at Onyx Pharmaceuticals where she provided strategy and advice on intellectual property related matters related to KYPROLIS and Elan Pharmaceuticals where she oversaw all intellectual property matters related to TYSABRI, the company humanized antibody product. Ms. Robbins began her career at Chiron Corporation and later joined the law firm of Burns, Doane, Swecker Mathis where she prepared and prosecuted U.S. and foreign patent applications in the biotechnology and pharmaceutical fields since 2019.
| Tenure | 6 years |
| Address | 151 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 |
| Phone | 650 515 3185 |
| Web | https://www.cytomx.com |
Robbins received her B.A. degree in microbiology and immunology from the University of California, Berkeley and her J.D. from the Illinois Institute of Technology ChicagoKent College of Law.
CytomX Therapeutics Management Efficiency
The company has return on total asset
(ROA) of
0.0233 % which means that it generated a profit of $0.0233 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity
(ROE) of
(54.7503) %, meaning that it created substantial loss on money invested by shareholders. CytomX Therapeutics' management efficiency ratios could be used to measure how well CytomX Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
Return On Equity is likely to rise to 0.01 in 2025, whereas
Return On Tangible Assets are likely to drop
(0) in 2025. At this time, CytomX Therapeutics'
Total Assets are fairly stable compared to the past year.
Non Currrent Assets Other is likely to rise to about 945
K in 2025, whereas
Non Current Assets Total are likely to drop slightly above 19.5
M in 2025.
CytomX Therapeutics currently holds 13.97
M in liabilities with Debt to Equity
(D/E) ratio of 0.67, which is about average as compared to similar companies. CytomX Therapeutics has a current ratio of 2.01, suggesting that it is
liquid enough and is able to pay its financial obligations when due. Note, when we think about CytomX Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California. Cytomx Thera operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 174 people. CytomX Therapeutics (CTMX) is traded on NASDAQ Exchange in USA. It is located in 151 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 and employs 120 people. CytomX Therapeutics is listed under Biotechnology category by Fama And French industry classification.
Management Performance
CytomX Therapeutics Leadership Team
Elected by the shareholders, the CytomX Therapeutics' board of directors comprises two types of representatives: CytomX Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CytomX. The board's role is to monitor CytomX Therapeutics' management team and ensure that shareholders' interests are well served. CytomX Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CytomX Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MBA BS, Head VP | |
| JD Rowland, General VP | |
| Danielle OlanderMoghadassian, Senior Officer | |
| YuWaye MD, Senior Officer | |
| Leslie Robbins, Senior Vice President - Intellectual Property | |
| Sean DPHIL, Chairman CEO | |
| Christopher Ogden, Principal Accounting | |
| Marcia Belvin, Senior Officer | |
| Chau MBA, Vice Communications | |
| Hoyoung MD, Special Officer | |
| Jamie Moore, VP Manufacturing | |
| Dawn Benson, Senior Manufacturing | |
| DPHIL DPhil, Chairman CEO | |
CytomX Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CytomX Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Tools for CytomX Stock Analysis
When running CytomX Therapeutics' price analysis, check to
measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to
predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.